Edwards Lifesciences Corp. (EW) Tops Q1 EPS by 9c; Increases FY11 EPS Outlook, Guides Q2
Edwards Lifesciences Corp. (NYSE: EW) reported Q1 EPS of $0.51, $0.09 better than the analyst estimate of $0.42. Revenue for the quarter came in at $404.5 million versus the consensus estimate of $384.15 million.
Sees Q2 2011 EPS of $0.49-$0.51, versus the consensus of $0.47.
Increases FY2011 EPS form $1.91 - $1.97 to $2.01-$2.07, versus the consensus of $1.95. Sees FY2011 revenue of $1.66-$1.74 billion, versus the consensus of $1.63 billion.
Sees Q2 2011 EPS of $0.49-$0.51, versus the consensus of $0.47.
Increases FY2011 EPS form $1.91 - $1.97 to $2.01-$2.07, versus the consensus of $1.95. Sees FY2011 revenue of $1.66-$1.74 billion, versus the consensus of $1.63 billion.